Item 2.02 Results of Operations and Financial Condition.

As previously announced, on January 14, 2021, Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel Therapeutics, Inc. (the "Company"), will be providing a presentation to investors at the 39th Annual J.P. Morgan Healthcare Conference (the "Conference") on Thursday, January 14, 2021 at 8:20 a.m., Eastern Time. In connection with the presentation, the Company is reporting that its estimated cash and cash equivalents totaled $213.1 million as of December 31, 2020. This amount is preliminary, has not been audited and is subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2020.

Item 7.01 Regulation FD Disclosure.

The live webcast and a copy of the accompanying presentation materials that will be used at the Conference will be available through the "Investors" page of the Company's website at http://www.bioxceltherapeutics.com.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses